Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (4) , 496-499
- https://doi.org/10.1093/jac/dki025
Abstract
Objectives: The aim of this study was to characterize the ampC β-lactamase gene of a clinical isolate of Serratia marcescens resistant to ceftazidime. Methods: S. marcescens SMSA was isolated from an intra-abdominal wound of a patient previously treated with ceftazidime. A susceptible strain, SLS73, was used as a control. Susceptibility testing, PCR, DNA sequencing, molecular cloning, site-directed mutagenesis and determination of kinetic parameters were carried out to investigate the mechanism of resistance to ceftazidime. Results: MICs of ceftazidime were 64 and 0.2 mg/L for SMSA and SLS73, respectively. Sequencing of the ampC gene of SMSA was carried out. When compared with the closest AmpC enzyme, the S. marcescens S3 β-lactamase, the novel protein showed E57Q, Q129K and S220Y substitutions. The S220Y substitution is located in the omega loop. Introduced by mutagenesis in the ampC gene of SLS73, this substitution conferred the same level of resistance to ceftazidime. The catalytic efficiency (kcat/Km) of the mutated enzyme toward ceftazidime was increased by about 100-fold. Conclusions: We present another example of in vivo selection of broad-spectrum resistance by amino acid substitution in the omega loop of chromosomal AmpC β-lactamase in S. marcescens.Keywords
This publication has 17 references indexed in Scilit:
- Resistance to Cefepime and Cefpirome Due to a 4-Amino-Acid Deletion in the Chromosome-Encoded AmpC β-Lactamase of a Serratia marcescens Clinical IsolateAntimicrobial Agents and Chemotherapy, 2004
- Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical IsolateAntimicrobial Agents and Chemotherapy, 2004
- Analyses of ampC gene expression in Serratia marcescens reveal new regulatory propertiesJournal of Antimicrobial Chemotherapy, 2003
- Mutation in Serratia marcescens AmpC β-Lactamase Producing High-Level Resistance to Ceftazidime and CefpiromeAntimicrobial Agents and Chemotherapy, 2001
- Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of anEnterobacter cloacaeclinical isolateFEMS Microbiology Letters, 2001
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Molecular evolution of bacterial β-lactam resistanceChemistry & Biology, 1996
- Protein Modeling by E-mailNature Biotechnology, 1995
- Type I -Lactamases of Gram-Negative Bacteria: Interactions with -Lactam AntibioticsThe Journal of Infectious Diseases, 1986
- Computerized microacidimetric determination of β lactamase Michaelis—Menten constantsFEBS Letters, 1973